Nirmatrelvir treatment shows no link to reduced long-COVID risk, study reveals

Recent study reveals nirmatrelvir treatment during acute COVID-19 does not lower the risk of post-acute COVID-19 symptoms, nor is it associated with symptomatic rebound.

The Endpoints Slack interview: Zavain Dar on starting a new VC, trusting the process with the 76ers, and Apple’s VR future

About a decade ago, the front office of the Philadelphia 76ers attempted a radically new way of running a professional basketball team, bringing the “moneyball”

February 14, 2024

atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine) | Psychedelic Invest

atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced results from Perception Neuroscience’s Phase 1

August 10, 2023

PAION AG cancelled guidance for financial year 2023 – Biotech Investments

PAION AG / Key word(s): Change in Forecast PAION AG cancelled guidance for financial year 2023 24-Nov-2023 / 13:46 CET/CEST Disclosure of an inside information

November 25, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.